Posted by Michael Wonder on 19 Aug 2022
FDA accepts Krystal Biotech’s biologics license application for dystrophic epidermolysis bullosa
18 August 2022 - FDA granted priority review designation.
Krystal Biotech today announced that the US FDA has accepted for filing the Company’s biologics license application for B-VEC for the treatment of patients with dystrophic epidermolysis bullosa.
